Pfizer Inc.
Moat Score — Pfizer Inc.
Total Moat Score
15 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Pfizer's moat rests on patent-protected drugs and vaccines, deep regulatory/clinical-trial expertise, and franchises like Prevnar and Vyndaqel, though patents are time-limited and erode as they expire. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 2 / 5 | Scale in R&D, manufacturing, and global commercial infrastructure helps, but Pfizer is not fundamentally a low-cost producer relative to similarly scaled big-pharma peers. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 4 / 5 | Patent-protected medicines command premium pricing with limited substitutes while under exclusivity, though U.S. drug-pricing policy, including Medicare price negotiation under the IRA, is actively compressing this advantage. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Pharmaceutical sales do not benefit from network effects — a drug's value to one patient is unrelated to how many other patients use it. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Physician prescribing habits and patient familiarity create some inertia, but generic and biosimilar substitution rapidly erodes this once patents expire, limiting durable switching costs. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | The enormous cost and risk of pharmaceutical R&D and regulatory approval limits the number of viable global competitors, but numerous well-capitalized big-pharma rivals (Merck, Lilly, Novartis, Roche) keep the space competitive rather than an efficient-scale near-monopoly. |